Sara Hall, Sweden
Skåne University Hospital Clinical Memory Research Unit, Memory ClinicAuthor Of 2 Presentations
LIVE DISCUSSION
PLASMA PHOSPHO-TAU IDENTIFIES ALZHEIMER’S CO-PATHOLOGY IN PATIENTS WITH LEWY BODY DISEASE WITH DEMENTIA
Abstract
Aims
To investigate whether plasma phospho-tau217 (P-tau217) and phospho-tau181 (P-tau181) can detect Alzheimer’s disease (AD) co-pathology in patients with dementia with Lewy bodies and Parkinson’s disease with dementia (i.e. Lewy body disease with dementia).
Methods
In this cross-sectional study we investigated the plasma levels of P-tau217 and P-tau181 in 35 patients with dementia with Lewy bodies or Parkinson’s disease with dementia, recruited as part of the Swedish BioFINDER2 study. All patients also underwent tau-PET imaging using 18F-RO948, and cerebrospinal fluid (CSF) was analyzed for P-tau217, P-tau181 and β-amyloid42/40 (Aβ42/Aβ40), biomarkers that reliably detect AD pathology in vivo. Abnormal β-amyloid status was defined as CSF Aβ42/Aβ40 <0.752, determined using mixture modeling.
Results
Plasma P-tau217 correlated with plasma P-tau181 (rs=0.68, p<0.001), CSF P-tau217 (rs=0.68, p<0.001) and negatively with CSF Aβ42/Aβ40 (rs=-0.52, p=0.001). Plasma P-tau181 correlated with CSF P-tau181 (rs=0.55, p<0.001). Both plasma P-tau217 and plasma P-tau181 correlated with 18F-RO948 retention in the temporal meta ROI corresponding to Braak stage I-IV (rs=0.57, p<0.001 and rs=0.66, p<0.001, respectively). Additionally, plasma P-tau217 and plasma P-tau181 predicted abnormal tau-PET status in the temporal meta ROI (AUC 0.84 and 0.78, respectively) as well as abnormal CSF β-amyloid status (AUC 0.88 and 0.81, respectively).
Conclusions
Plasma P-tau might be a useful marker for the detection of AD co-pathology in Lewy body disease with dementia, and could be used for stratification of patients in clinical trials. Further studies are needed to determine whether plasma P-tau provides important prognostic information in patients with Lewy body disease.
Presenter of 2 Presentations
PLASMA PHOSPHO-TAU IDENTIFIES ALZHEIMER’S CO-PATHOLOGY IN PATIENTS WITH LEWY BODY DISEASE WITH DEMENTIA
Abstract
Aims
To investigate whether plasma phospho-tau217 (P-tau217) and phospho-tau181 (P-tau181) can detect Alzheimer’s disease (AD) co-pathology in patients with dementia with Lewy bodies and Parkinson’s disease with dementia (i.e. Lewy body disease with dementia).
Methods
In this cross-sectional study we investigated the plasma levels of P-tau217 and P-tau181 in 35 patients with dementia with Lewy bodies or Parkinson’s disease with dementia, recruited as part of the Swedish BioFINDER2 study. All patients also underwent tau-PET imaging using 18F-RO948, and cerebrospinal fluid (CSF) was analyzed for P-tau217, P-tau181 and β-amyloid42/40 (Aβ42/Aβ40), biomarkers that reliably detect AD pathology in vivo. Abnormal β-amyloid status was defined as CSF Aβ42/Aβ40 <0.752, determined using mixture modeling.
Results
Plasma P-tau217 correlated with plasma P-tau181 (rs=0.68, p<0.001), CSF P-tau217 (rs=0.68, p<0.001) and negatively with CSF Aβ42/Aβ40 (rs=-0.52, p=0.001). Plasma P-tau181 correlated with CSF P-tau181 (rs=0.55, p<0.001). Both plasma P-tau217 and plasma P-tau181 correlated with 18F-RO948 retention in the temporal meta ROI corresponding to Braak stage I-IV (rs=0.57, p<0.001 and rs=0.66, p<0.001, respectively). Additionally, plasma P-tau217 and plasma P-tau181 predicted abnormal tau-PET status in the temporal meta ROI (AUC 0.84 and 0.78, respectively) as well as abnormal CSF β-amyloid status (AUC 0.88 and 0.81, respectively).
Conclusions
Plasma P-tau might be a useful marker for the detection of AD co-pathology in Lewy body disease with dementia, and could be used for stratification of patients in clinical trials. Further studies are needed to determine whether plasma P-tau provides important prognostic information in patients with Lewy body disease.
LIVE DISCUSSION